"remdesivir’s polymerase inhibitor mechanism can reduce viral load, experts said. However, all available data is still empirical in nature, and load reduction may not translate into clinically relevant outcomes like reducing hospital stay or decreasing mortality (https://www.pharmaceutical-technology.com/comment/gilead-rem...)
Remdesivir is an element similar to one the cells use to create protein chains. When used instead of the real element it stops the chain. This limits the ability of the virus to create new copies.
Remdesivir is difficult to make. About 8 liters of starting material is used to create a milli-liter of product which is about 1 injections. It appears that each patient may require multiple injections.
Remdesivir is not a vaccine.
Remdesivir might reduce viral load (number of virus particles). The relationship between viral load, which is high in the beginning but less later, does not necessarily translate to sickness or death.
Remdesivir has never had a single commercial application. It is a drug that has failed at everything.
The one high quality RCT published in the Lancet found likelihood of no effect on recovery. All the hype you see now is based on a press release with no substantive information about the study, its methodolody, statistical analysis, or secondary outcomes.
It could end up actually useful. But don't let the drugmaker bamboozle you into thinking it's so without good data.
2 comments
[ 762 ms ] story [ 2964 ms ] threadRemdesivir is an element similar to one the cells use to create protein chains. When used instead of the real element it stops the chain. This limits the ability of the virus to create new copies.
Remdesivir is difficult to make. About 8 liters of starting material is used to create a milli-liter of product which is about 1 injections. It appears that each patient may require multiple injections.
Remdesivir is not a vaccine.
Remdesivir might reduce viral load (number of virus particles). The relationship between viral load, which is high in the beginning but less later, does not necessarily translate to sickness or death.
The one high quality RCT published in the Lancet found likelihood of no effect on recovery. All the hype you see now is based on a press release with no substantive information about the study, its methodolody, statistical analysis, or secondary outcomes.
It could end up actually useful. But don't let the drugmaker bamboozle you into thinking it's so without good data.